Photocure ASA (OSL:PHO)
Norway · Delayed Price · Currency is NOK 63.40
-0.20 (-0.31%)
Aug 5, 2025, 4:25 PM CET
G1 Therapeutics Income Statement
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Operating Revenue | 522.86 | 525.39 | 500.66 | 393.13 | 360.54 | 256.48 | Upgrade |
Other Revenue | -0 | -0 | - | - | - | - | Upgrade |
| 522.86 | 525.39 | 500.66 | 393.13 | 360.54 | 256.48 | Upgrade | |
Revenue Growth (YoY) | 1.81% | 4.94% | 27.35% | 9.04% | 40.57% | -8.91% | Upgrade |
Cost of Revenue | 34.53 | 30.72 | 26.14 | 22.7 | 24.05 | 18.51 | Upgrade |
Gross Profit | 488.33 | 494.67 | 474.52 | 370.44 | 336.49 | 237.97 | Upgrade |
Selling, General & Admin | 373.35 | 371.15 | 347.56 | 318.81 | 274.7 | 200.56 | Upgrade |
Research & Development | 3.43 | 3.63 | 2.07 | 3.34 | 4.32 | 13.84 | Upgrade |
Other Operating Expenses | 110.68 | 99.49 | 97.09 | 97.29 | 63.3 | 46.78 | Upgrade |
Operating Expenses | 487.45 | 474.27 | 446.71 | 419.44 | 342.32 | 261.18 | Upgrade |
Operating Income | 0.88 | 20.4 | 27.81 | -49 | -5.83 | -23.2 | Upgrade |
Interest Expense | -25.95 | -28.03 | -26.33 | -25.8 | -23.83 | -7.03 | Upgrade |
Interest & Investment Income | 11.28 | 12.87 | 11.71 | 2.34 | 1.81 | 5.66 | Upgrade |
Currency Exchange Gain (Loss) | 3.2 | 3.2 | -2.01 | 2.29 | 13.31 | 4.97 | Upgrade |
Other Non Operating Income (Expenses) | -0.04 | -0.04 | -1.44 | -0.96 | -17.12 | -0.77 | Upgrade |
EBT Excluding Unusual Items | -10.64 | 8.39 | 9.74 | -71.13 | -31.66 | -20.37 | Upgrade |
Merger & Restructuring Charges | - | - | - | - | - | -12.85 | Upgrade |
Pretax Income | -10.64 | 8.39 | 9.74 | -71.13 | -31.66 | -33.23 | Upgrade |
Income Tax Expense | -5.31 | 11.73 | 8.76 | 0.72 | -0.76 | -10.82 | Upgrade |
Net Income | -5.33 | -3.34 | 0.98 | -71.86 | -30.9 | -22.4 | Upgrade |
Net Income to Common | -5.33 | -3.34 | 0.98 | -71.86 | -30.9 | -22.4 | Upgrade |
Shares Outstanding (Basic) | 27 | 27 | 27 | 27 | 27 | 25 | Upgrade |
Shares Outstanding (Diluted) | 27 | 27 | 27 | 27 | 27 | 25 | Upgrade |
Shares Change (YoY) | -0.74% | -0.10% | 0.36% | 0.71% | 9.02% | 12.76% | Upgrade |
EPS (Basic) | -0.20 | -0.12 | 0.04 | -2.66 | -1.15 | -0.91 | Upgrade |
EPS (Diluted) | -0.20 | -0.12 | 0.04 | -2.66 | -1.15 | -0.91 | Upgrade |
Free Cash Flow | 33.13 | 65.3 | 36 | -5.63 | 20.18 | 14.4 | Upgrade |
Free Cash Flow Per Share | 1.23 | 2.41 | 1.33 | -0.21 | 0.75 | 0.58 | Upgrade |
Gross Margin | 93.40% | 94.15% | 94.78% | 94.23% | 93.33% | 92.78% | Upgrade |
Operating Margin | 0.17% | 3.88% | 5.55% | -12.46% | -1.62% | -9.05% | Upgrade |
Profit Margin | -1.02% | -0.64% | 0.20% | -18.28% | -8.57% | -8.73% | Upgrade |
Free Cash Flow Margin | 6.34% | 12.43% | 7.19% | -1.43% | 5.60% | 5.61% | Upgrade |
EBITDA | 19.99 | 42.06 | 47.59 | -31.02 | 11.96 | -17.98 | Upgrade |
EBITDA Margin | 3.82% | 8.01% | 9.50% | -7.89% | 3.32% | -7.01% | Upgrade |
D&A For EBITDA | 19.12 | 21.66 | 19.78 | 17.98 | 17.79 | 5.23 | Upgrade |
EBIT | 0.88 | 20.4 | 27.81 | -49 | -5.83 | -23.2 | Upgrade |
EBIT Margin | 0.17% | 3.88% | 5.55% | -12.46% | -1.62% | -9.05% | Upgrade |
Effective Tax Rate | - | 139.81% | 89.95% | - | - | - | Upgrade |
Revenue as Reported | 522.86 | 525.39 | 500.66 | 393.13 | 360.54 | 256.48 | Upgrade |
Updated Feb 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.